News stories about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.0747703182222 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Amphastar Pharmaceuticals (AMPH) opened at $18.32 on Friday. The firm has a market cap of $842.73, a price-to-earnings ratio of 122.20 and a beta of 1.69. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The business had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 EPS. equities research analysts expect that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

AMPH has been the subject of a number of research reports. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Raymond James Financial cut shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective for the company. in a research note on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Sunday, September 17th. BMO Capital Markets upped their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research note on Friday, November 10th. Finally, Jefferies Group set a $19.00 price target on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $20.86.

In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $18.04, for a total value of $141,830.48. Following the completion of the transaction, the director now directly owns 31,978 shares in the company, valued at approximately $576,883.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 3,026 shares of the company’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $18.56, for a total transaction of $56,162.56. The disclosure for this sale can be found here. Insiders sold a total of 186,666 shares of company stock valued at $3,451,064 over the last 90 days. Company insiders own 11.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.